Esperion Therapeutis.Inc. buy Cantor Fitzgerald
Start price
17.12.24
/
50%
€2.41
Target price
17.12.25
€7.61
Performance (%)
41.71%
Price
28.11.25
€3.41
Summary
This prediction is currently active. With a performance of 41.71% the BUY prediction by Cantor_Fitzgerald is a big success. This prediction currently runs until 17.12.25. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Esperion Therapeutis.Inc. | 27.753% | 27.753% |
| iShares Core DAX® | 2.705% | -1.771% |
| iShares Nasdaq 100 | 4.127% | -1.874% |
| iShares Nikkei 225® | 1.944% | -3.187% |
| iShares S&P 500 | 2.919% | -0.149% |
Comments by Cantor_Fitzgerald for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $8.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat
Stopped prediction by Cantor_Fitzgerald for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€2.78
12.11.25
12.11.25
-
12.11.26
12.11.26
22.83%
28.11.25
28.11.25
